Merck in Talks to Buy Revolution Medicines Per Financial Times Report
ZACKS·2026-01-09 18:06

Key Takeaways RVMD is in takeover talks with a valuation range of about $28B-$32B, though a deal is not yet finalized.Merck would add daraxonrasib, a late-stage RAS(ON) inhibitor being tested in pancreatic and lung cancers.MRK has pursued multiple acquisitions to offset Keytruda's 2028 loss of exclusivity.A recent Financial Times report stated that Merck (MRK) is in talks to buy Redwood City, CA-based cancer biotech, Revolution Medicines (RVMD) , in a transaction that could value RVMD for up to $32 billion. ...